Frontline systemic therapy with pemetrexed-platinum in nonsquamous non-small-cell lung cancer with asymptomatic brain metastases

Samer Alsidawi, Rekha Chaudhary, Nagla A. Karim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The incidence of brain metastases from nonsquamous non-small-lung cancer is increasing as a result of superior imaging techniques for early detection of distant metastases. Although whole-brain radiation therapy and stereotactic radiosurgery along with systemic chemotherapy have shown to be effective in alleviating symptoms and improving outcomes, the approach to patients with asymptomatic brain metastases remains elusive. We explored the literature for a possible role of frontline systemic chemotherapy in asymptomatic brain metastases from nonsquamous non-small-lung cancer and found promising evidence that upfront systemic therapy with pemetrexed-platinum regimens might be a reasonable option for these patients and would forestall the need for upfront brain radiation therapy. More large-scale phase II and phase III clinical trials are needed to further investigate the frontline use of pemetrexed-platinum regimens in this setting.

Original languageEnglish (US)
Pages (from-to)e111-e120
JournalAmerican journal of therapeutics
Volume24
Issue number2
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Pemetrexed
Platinum
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Lung Neoplasms
Radiotherapy
Therapeutics
Drug Therapy
Phase III Clinical Trials
Radiosurgery
Incidence

Keywords

  • Brain metastases
  • Frontline chemotherapy
  • Nonsquamous non-small-cell lung cancer
  • Pemetrexed
  • Platinums

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Frontline systemic therapy with pemetrexed-platinum in nonsquamous non-small-cell lung cancer with asymptomatic brain metastases. / Alsidawi, Samer; Chaudhary, Rekha; Karim, Nagla A.

In: American journal of therapeutics, Vol. 24, No. 2, 01.01.2017, p. e111-e120.

Research output: Contribution to journalArticle

@article{46a8cd6d185f4e3e9684f2bb6d44d9d4,
title = "Frontline systemic therapy with pemetrexed-platinum in nonsquamous non-small-cell lung cancer with asymptomatic brain metastases",
abstract = "The incidence of brain metastases from nonsquamous non-small-lung cancer is increasing as a result of superior imaging techniques for early detection of distant metastases. Although whole-brain radiation therapy and stereotactic radiosurgery along with systemic chemotherapy have shown to be effective in alleviating symptoms and improving outcomes, the approach to patients with asymptomatic brain metastases remains elusive. We explored the literature for a possible role of frontline systemic chemotherapy in asymptomatic brain metastases from nonsquamous non-small-lung cancer and found promising evidence that upfront systemic therapy with pemetrexed-platinum regimens might be a reasonable option for these patients and would forestall the need for upfront brain radiation therapy. More large-scale phase II and phase III clinical trials are needed to further investigate the frontline use of pemetrexed-platinum regimens in this setting.",
keywords = "Brain metastases, Frontline chemotherapy, Nonsquamous non-small-cell lung cancer, Pemetrexed, Platinums",
author = "Samer Alsidawi and Rekha Chaudhary and Karim, {Nagla A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MJT.0000000000000106",
language = "English (US)",
volume = "24",
pages = "e111--e120",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Frontline systemic therapy with pemetrexed-platinum in nonsquamous non-small-cell lung cancer with asymptomatic brain metastases

AU - Alsidawi, Samer

AU - Chaudhary, Rekha

AU - Karim, Nagla A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The incidence of brain metastases from nonsquamous non-small-lung cancer is increasing as a result of superior imaging techniques for early detection of distant metastases. Although whole-brain radiation therapy and stereotactic radiosurgery along with systemic chemotherapy have shown to be effective in alleviating symptoms and improving outcomes, the approach to patients with asymptomatic brain metastases remains elusive. We explored the literature for a possible role of frontline systemic chemotherapy in asymptomatic brain metastases from nonsquamous non-small-lung cancer and found promising evidence that upfront systemic therapy with pemetrexed-platinum regimens might be a reasonable option for these patients and would forestall the need for upfront brain radiation therapy. More large-scale phase II and phase III clinical trials are needed to further investigate the frontline use of pemetrexed-platinum regimens in this setting.

AB - The incidence of brain metastases from nonsquamous non-small-lung cancer is increasing as a result of superior imaging techniques for early detection of distant metastases. Although whole-brain radiation therapy and stereotactic radiosurgery along with systemic chemotherapy have shown to be effective in alleviating symptoms and improving outcomes, the approach to patients with asymptomatic brain metastases remains elusive. We explored the literature for a possible role of frontline systemic chemotherapy in asymptomatic brain metastases from nonsquamous non-small-lung cancer and found promising evidence that upfront systemic therapy with pemetrexed-platinum regimens might be a reasonable option for these patients and would forestall the need for upfront brain radiation therapy. More large-scale phase II and phase III clinical trials are needed to further investigate the frontline use of pemetrexed-platinum regimens in this setting.

KW - Brain metastases

KW - Frontline chemotherapy

KW - Nonsquamous non-small-cell lung cancer

KW - Pemetrexed

KW - Platinums

UR - http://www.scopus.com/inward/record.url?scp=84906298297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906298297&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000106

DO - 10.1097/MJT.0000000000000106

M3 - Article

C2 - 25153672

AN - SCOPUS:84906298297

VL - 24

SP - e111-e120

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -